Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-part, open-label, randomised, cross-over study to compare new tablet formulations of RO7486967 to the capsule formulation, to perform a preliminary dose proportionality assessment and to estimate the effect of food on the pharmacokinetics of the tablet formulations in healthy participants

Next Previous
Search
Trial Profile

A two-part, open-label, randomised, cross-over study to compare new tablet formulations of RO7486967 to the capsule formulation, to perform a preliminary dose proportionality assessment and to estimate the effect of food on the pharmacokinetics of the tablet formulations in healthy participants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 23 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Selnoflast (Primary)
  • Indications Asthma; Chronic obstructive pulmonary disease; Inflammatory bowel diseases; Parkinson's disease
  • Focus Pharmacokinetics
  • Acronyms QSC205468
  • Sponsors Roche

    • Most Recent Events

    • 23 Sep 2022 Status changed from recruiting to completed.
    • 01 Jun 2022 Status changed from not yet recruiting to recruiting.
    • 01 Jun 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top